Pfizer reports positive data from RA drug trial
9 November 2010 00:00 in Pharmaceutical Company Product News
Pfizer has published new clinical data which supports the efficacy of its developmental therapy for moderate-to-severe rheumatoid arthritis (RA).
Results from the first phase III trial of tasocitinib, an oral JAK inhibitor, showed that it can deliver significant improvements in signs and symptoms of the disease compared to placebo, as well as helping patients to maintain physical function.
It means the drug met two of its primary endpoints in the study, while it was also shown to be associated with a greater number of cases of disease remission.
This comes after data from an earlier phase II/III trial showed that tasocitinib can deliver sustained effectiveness over 24 months, whether administered as a monotherapy or in combination with methotrexate.
Dr Roy Fleischmann, clinical professor at the University of Texas Southwestern Medical Center, said: "We are encouraged by the statistically significant and clinically meaningful improvements we observed in a proportion of patients treated with tasocitinib."
Earlier this month, the company posted its financial results for the third quarter of 2010, reporting significant year-on-year growth following its late 2009 merger with Wyeth.
Other news stories from 09/11/2010
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency